Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

PURPOSE: Contrary to the approved indication for pegfilgrastim prophylaxis, some patients receive it on the same day as the last administration of chemotherapy in clinical practice, which could adversely impact risk of febrile neutropenia (FN). An evaluation of the timing of pegfilgrastim prophylaxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Weycker, Derek, Li, Xiaoyan, Figueredo, Jacqueline, Barron, Rich, Tzivelekis, Spiros, Hagiwara, May
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805705/
https://www.ncbi.nlm.nih.gov/pubmed/26607482
http://dx.doi.org/10.1007/s00520-015-3036-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805705/
https://www.ncbi.nlm.nih.gov/pubmed/26607482
http://dx.doi.org/10.1007/s00520-015-3036-7

Ejemplares similares